Bonesupport Holding Ab · OMXSTO:BONEX
Bonesupport Holding Ab — Q3 2026 Earnings Presentation
19 slides from Bonesupport Holding Ab's earnings presentation, Oct 22, 2026
Slide 1: Q3 (2026) Report
BONESUPPORT Q3 (2026) Report October 22, 2026 Torbjörn Sköld, CEO Håkan Johansson, CFO Dr. Michael Diefenbeck, CMO
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements regarding BONESUPPORT HOLDING AB (publ) (“BONESUPPORT”), including, but not limited to, statements about future operations, financial performance, market conditions, growth strategies, product development, regulatory approvals, and oth
Slide 3: Third quarter report 2026 – Financial and operational highlights
BONESUPPORT – Third quarter report 2026 Financial highlights • Net sales SEK 408.8 m (SEK 294.1 m) Sales growth at constant exchange rates (CER): +38% Reported growth: +39% versus Q3 2025 • Operating results Adjusted Operating result1: SEK 139.3 m (SEK 78.6 m), resulting in adj. Operating margin of
Slide 4: Continued strong momentum for CERAMENT G in the US
Continued strong momentum for CERAMENT G in the US LTM Reported Net Sales (SEK m) by Segment and Quarter 1,500 1,401 1,350 1,286 • LTM growth of 31% in constant currencies, 1,215 1,175 versus 25% in the graph (reported) 1,200 1,119 1,062 1,050 998 • US CERAMENT BVF (LTM) flat in Q3 2026 compared to
Slide 5: US: Increasing customer access and adoption for CERAMENT G
US: Increasing customer access and adoption for CERAMENT G Q3 2026 • Sales of SEK 344.4 m (SEK 246.3 m). Growth of 40% over Q3 2025 • Growth of 39% at CER Highlights • Growth of CERAMENT G: ‒ Access (new accounts & surgeons) – strong across all market segments ‒ Adoption (existing accounts & surgeon
Slide 6: EUROW: Strong growth across markets
EUROW: Strong growth across markets Q3 2026 • Sales of SEK 64.4 m (SEK 47.8 m), growth of 35% over Q3 2025 • Growth of 34% at CER • Strong growth, even adjusting for the prior-year base and new distributor stocking orders (AUS & NZ) Highlights • Direct Markets delivered at solid growth rates across
Slide 7: SOLARIO - Short or Long Antibiotic Regimens in Orthopedics
SOLARIO - Short or Long Antibiotic Regimens in Orthopedics New England Journal of Medicine McNally M, Dudareva M, Kümin M, Vach W, Scarborough CL et al. N Engl J Med. 2026 Sep 16:10.1056/NEJMoa2506756. Epub ahead of print Background: Orthopedic infection is usually managed with surgery , local antib
Slide 8: SOLARIO - Short or Long Antibiotic Regimens in Orthopedics
SOLARIO - Short or Long Antibiotic Regimens in Orthopedics New England Journal of Medicine McNally M, Dudareva M, Kümin M, Vach W, Scarborough CL et al. N Engl J Med. 2026 Sep 16:10.1056/NEJMoa2506756. Epub ahead of print Results: 500 patients underwent randomization; 475 were assessed in the primar
Slide 9: SOLARIO - Short or Long Antibiotic Regimens in Orthopedics
SOLARIO - Short or Long Antibiotic Regimens in Orthopedics New England Journal of Medicine McNally M, Dudareva M, Kümin M, Vach W, Scarborough CL et al. N Engl J Med. 2026 Sep 16:10.1056/NEJMoa2506756. Epub ahead of print Results: 500 patients underwent randomization; 475 were assessed in the primar
Slide 10: SOLARIO - Short or Long Antibiotic Regimens in Orthopedics
SOLARIO - Short or Long Antibiotic Regimens in Orthopedics New England Journal of Medicine McNally M, Dudareva M, Kümin M, Vach W, Scarborough CL et al. N Engl J Med. 2026 Sep 16:10.1056/NEJMoa2506756. Epub ahead of print Conclusions: Among patients who had undergone orthopedic surgery and received
Slide 11: Financial Report
BONESUPPORT Q3 (2026) Report Financial Report
Slide 12: Q3 Net sales growth reached 38% in CER
Q3 Net sales growth reached 38% in CER Q3 Net sales vs PY Increase Decrease Total 450.0 16.3 3.6 408.8 400.0 94.8 • US growth reported at 40% (39% in CER). 350.0 300.0 294.1 • EUROW growth reported at 35% Net sales, SEKm (34% in CER). 250.0 200.0 150.0 100.0 50.0 0.0 Org growth US fx Q3 2025 Org gro
Slide 13: Continued strong CG performance in the US
Continued strong CG performance in the US Sales CERAMENT G - US per quarter 35.0 500 450 • Strong access and adoption 30.0 with a high and stable pace Net sales per working day, USD k 400 across all three market 25.0 350 segments. Net sales, USD m 300 20.0 250 15.0 200 10.0 150 100 5.0 50 0.0 0 Q4 2
Slide 14: US and EUROW net sales and gross margin
+40% +35% (+39% CER) (+34% CER) US Net sales Q3-26 EUROW Net sales Q3-26 North America 2026 2025 EUROW 2026 2025 SEK m Q3 Q2 Q1 Q4 Q3 SEK m Q3 Q2 Q1 Q4 Q3 Net sales 344.4 295.2 267.1 258.8 246.3 Net sales 64.4 60.7 56.7 53.8 47.8 Gross profit 323.7 276.9 252.3 245.3 234.8 Gross profit 52.7 49.0 46.5
Slide 15: Commercial investments increasing selling expenses
Commercial investments increasing selling expenses Key Figures 2026 2025 2024 SEK m Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Selling expenses 83.9 83.4 84.5 79.8 66.3 67.2 73.0 71.2 Sales Commissions and fees 111.4 95.3 85.7 85.6 85.1 79.4 79.3 70.4 Research and Development expenses 27.2 24.8 25.1 23.5 20.6 23.6 23.
Slide 16: Continued strong operating leverage and cash conversion
Continued strong operating leverage and cash conversion Key Figures 2026 2025 2024 SEK m Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Net sales 408.8 355.7 324.0 312.5 294.1 284.4 283.5 257.0 Gross margin (%) 92.0 90.8 92.2 92.5 92.9 92.3 92.6 92.6 Operating profit 123.4 89.6 72.2 81.8 65.4 54.9 29.6 64.2 Adj. Operating
Slide 17: Solid Operating margin continuing to improve
Solid Operating margin continuing to improve after a period of commercial investments 150 11.10 Adjusted operating result1 in SEK m 125 10.75 100 10.40 USD rate 75 10.05 50 9.70 25 9.35 0 9.00 Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Q4-24 Q1-25 Q2-25 Q3-25 Q4-25 Q1-26 Q2-26 Q3-26 USD Rate Adjusted
Slide 18: Continued solid cash flow
Continued solid cash flow Cash flow from operating activities 150.0 140% Cash conversion1 between 64-126 % from Q3 2024 and Cash flow from operation, SEK m 125.0 120% onwards 100% - Average 83% Cash conversion 100.0 80% 75.0 60% 50.0 40% 25.0 20% 0.0 0% 24 Q3 24 Q4 25 Q1 25 Q2 25 Q3 25 Q4 26 Q1 26 Q
Slide 19: Q3 (2026) Report summary and guidance
BONESUPPORT Q3 (2026) Report • 38% Net sales growth at CER ‒ US 40% and EUROW 34% at CER • Operating margin of 34% • Cash flow from operations SEK 138 m, buy back SEK 60 m and cash position SEK 511 m • SOLARIO published in NEJM • CMS reimbursement for CERAMENT G confirmed • CERAMENT V De Novo data p